Literature DB >> 31848775

The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Dorit Ben-Shachar1.   

Abstract

Parkinson's disease (PD) and schizophrenia (SZ) are two CNS disorders in which dysfunctions in the dopaminergic system and mitochondria are major pathologies. The symptomology of both, PD a neurodegenerative disorder and SZ a neurodevelopmental disorder, is completely different. However, the pharmacological treatment of each of the diseases can cause a shift of symptoms into those characteristic of the other disease. In this review, I describe a pathological interaction between dopamine and mitochondria in both disorders, which due to differences in the extent of oxidative stress leads either to cell death and tissue degeneration as in PD substantia nigra pars compacta or to distorted neuronal activity, imbalanced neuronal circuitry and abnormal behavior and cognition in SZ. This review is in the honor of Moussa Youdim who introduced me to the secrets of research work. His enthusiasm, curiosity and novelty-seeking inspired me throughout my career. Thank you Moussa.

Entities:  

Keywords:  Complex I; Dopamine; Mitochondria; Parkinson’s disease; Schizophrenia

Year:  2019        PMID: 31848775     DOI: 10.1007/s00702-019-02120-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  133 in total

1.  The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses.

Authors:  Zheng Li; Ken-Ichi Okamoto; Yasunori Hayashi; Morgan Sheng
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

Review 2.  The positive-negative distinction in schizophrenia. Review of natural history validators.

Authors:  T H McGlashan; W S Fenton
Journal:  Arch Gen Psychiatry       Date:  1992-01

3.  NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia.

Authors:  Oded Bergman; Rachel Karry; Jumana Milhem; Dorit Ben-Shachar
Journal:  Mol Psychiatry       Date:  2018-12-10       Impact factor: 15.992

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 5.  Comprehensive review: Computational modelling of schizophrenia.

Authors:  Vincent Valton; Liana Romaniuk; J Douglas Steele; Stephen Lawrie; Peggy Seriès
Journal:  Neurosci Biobehav Rev       Date:  2017-09-01       Impact factor: 8.989

Review 6.  Genetics of Schizophrenia: Historical Insights and Prevailing Evidence.

Authors:  J van de Leemput; J L Hess; S J Glatt; M T Tsuang
Journal:  Adv Genet       Date:  2016-09-27       Impact factor: 1.944

7.  Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson's Disease.

Authors:  Alice Biosa; Irene Arduini; Maria Eugenia Soriano; Valentina Giorgio; Paolo Bernardi; Marco Bisaglia; Luigi Bubacco
Journal:  ACS Chem Neurosci       Date:  2018-07-03       Impact factor: 4.418

8.  Mitochondrial complex I as a novel target for intraneuronal DA: modulation of respiration in intact cells.

Authors:  Hanit Brenner-Lavie; Ehud Klein; Dorit Ben-Shachar
Journal:  Biochem Pharmacol       Date:  2009-04-02       Impact factor: 5.858

9.  Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.

Authors:  D Ben-Shachar; P Riederer; M B Youdim
Journal:  J Neurochem       Date:  1991-11       Impact factor: 5.372

10.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more
  3 in total

Review 1.  Therapeutic targeting of mitophagy in Parkinson's disease.

Authors:  Shashank Masaldan; Sylvie Callegari; Grant Dewson
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

Review 2.  Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.

Authors:  Matej Ľupták; Danica Michaličková; Zdeněk Fišar; Eva Kitzlerová; Jana Hroudová
Journal:  World J Psychiatry       Date:  2021-07-19

3.  The Relationship between the Level of Anterior Cingulate Cortex Metabolites, Brain-Periphery Redox Imbalance, and the Clinical State of Patients with Schizophrenia and Personality Disorders.

Authors:  Amira Bryll; Wirginia Krzyściak; Paulina Karcz; Natalia Śmierciak; Tamas Kozicz; Justyna Skrzypek; Marta Szwajca; Maciej Pilecki; Tadeusz J Popiela
Journal:  Biomolecules       Date:  2020-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.